Publications by authors named "Cecile Dorange"

Claim this Profile
P
Plain language summary of the CheckMate 816 study results: nivolumab plus chemotherapy given before surgery for non-small-cell lung cancer.
Patrick M Forde, Jonathan Spicer, Shun Lu, Mariano Provencio, Tetsuya Mitsudomi, Cecile Dorange

Future Oncol· March 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Neoadjuvant Nivolumab plus Chemotherapy in Resectable Lung Cancer.
Patrick M Forde, Jonathan Spicer, Shun Lu, Mariano Provencio, Tetsuya Mitsudomi, Cecile Dorange

N Engl J Med· May 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
CheckMate-032 Study: Efficacy and Safety of Nivolumab and Nivolumab Plus Ipilimumab in Patients With Metastatic Esophagogastric Cancer.
Yelena Y Janjigian, Johanna Bendell, Emiliano Calvo, Joseph W Kim, Paolo A Ascierto, Cecile Dorange

J Clin Oncol· October 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer.
Hossein Borghaei, Luis Paz-Ares, Leora Horn, David R Spigel, Martin Steins, Cécile Dorange

N Engl J Med· October 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The ABSORB EXTEND study: preliminary report of the twelve-month clinical outcomes in the first 512 patients enrolled.
Alexandre Abizaid, J Ribamar Costa, Antonio L Bartorelli, Robert Whitbourn, Robert Jan van Geuns, Cécile Dorange

EuroIntervention· April 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Circumferential distribution of the neointima at six-month and two-year follow-up after a bioresorbable vascular scaffold implantation: a substudy of the ABSORB Cohort B Clinical Trial.
Christos V Bourantas, Vasim Farooq, Yaojun Zhang, Takashi Muramatsu, Bill D Gogas, Cecile Dorange

EuroIntervention· March 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Procedural and clinical outcomes of the Absorb everolimus-eluting bioresorbable vascular scaffold: one-month results of the Bioresorbable vascular Scaffold Evaluated At Rotterdam Cardiology Hospitals (B-SEARCH).
Cihan Simsek, Michael Magro, Yoshinobu Onuma, Eric Boersma, Peter Smits, Cecile Dorange

EuroIntervention· June 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
1
1-year clinical outcomes of diabetic patients treated with everolimus-eluting bioresorbable vascular scaffolds: a pooled analysis of the ABSORB and the SPIRIT trials.
Takashi Muramatsu, Yoshinobu Onuma, Robert-Jan van Geuns, Bernard Chevalier, Tejas M Patel, Cécile C Dorange

JACC Cardiovasc Interv· May 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Dynamics of vessel wall changes following the implantation of the absorb everolimus-eluting bioresorbable vascular scaffold: a multi-imaging modality study at 6, 12, 24 and 36 months.
Patrick W Serruys, Yoshinobu Onuma, Hector M Garcia-Garcia, Takashi Muramatsu, Robert-Jan van Geuns, Cecile Dorange

EuroIntervention· March 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effect of the endothelial shear stress patterns on neointimal proliferation following drug-eluting bioresorbable vascular scaffold implantation: an optical coherence tomography study.
Christos V Bourantas, Michail I Papafaklis, Anna Kotsia, Vasim Farooq, Takashi Muramatsu, Cecile Dorange

JACC Cardiovasc Interv· March 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The edge vascular response following implantation of the Absorb everolimus-eluting bioresorbable vascular scaffold and the XIENCE V metallic everolimus-eluting stent. First serial follow-up assessment at six months and two years: insights from the first-in-man ABSORB Cohort B and SPIRIT II trials.
Bill D Gogas, Christos V Bourantas, Hector M Garcia-Garcia, Yoshinobu Onuma, Takashi Muramatsu, Cecile Dorange

EuroIntervention· October 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Evaluation of the XIENCE V everolimus eluting coronary stent system in the Asian population of the SPIRIT V single arm study. 2-year clinical follow-up data.
Upendra Kaul, Tejas M Patel, Robaayah Zambahari, Ajit S Mullasari, Vinay K Bahl, Cécile Dorange

Indian Heart J· August 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
ABSORB II randomized controlled trial: a clinical evaluation to compare the safety, efficacy, and performance of the Absorb everolimus-eluting bioresorbable vascular scaffold system against the XIENCE everolimus-eluting coronary stent system in the treatment of subjects with ischemic heart disease caused by de novo native coronary artery lesions: rationale and study design.
Roberto Diletti, Patrick W Serruys, Vasim Farooq, Krishnankutty Sudhir, Cecile Dorange

Am Heart J· November 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
First serial assessment at 6 months and 2 years of the second generation of absorb everolimus-eluting bioresorbable vascular scaffold: a multi-imaging modality study.
John A Ormiston, Patrick W Serruys, Yoshinobu Onuma, Robert-Jan van Geuns, Bernard de Bruyne, Cecile Dorange

Circ Cardiovasc Interv· October 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Analysis of 1 year virtual histology changes in coronary plaque located behind the struts of the everolimus eluting bioresorbable vascular scaffold.
Salvatore Brugaletta, Josep Gomez-Lara, Hector M Garcia-Garcia, Jung Ho Heo, Vasim Farooq, Cecile Dorange

Int J Cardiovasc Imaging· August 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Angiographic maximal luminal diameter and appropriate deployment of the everolimus-eluting bioresorbable vascular scaffold as assessed by optical coherence tomography: an ABSORB cohort B trial sub-study.
Josep Gomez-Lara, Roberto Diletti, Salvatore Brugaletta, Yoshinobu Onuma, Vasim Farooq, Cécile Dorange

EuroIntervention· June 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Endothelial-dependent vasomotion in a coronary segment treated by ABSORB everolimus-eluting bioresorbable vascular scaffold system is related to plaque composition at the time of bioresorption of the polymer: indirect finding of vascular reparative therapy?
Salvatore Brugaletta, Jung Ho Heo, Hector M Garcia-Garcia, Vasim Farooq, Robert Jan van Geuns, Cecile Dorange

Eur Heart J· June 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
V
Vascular response of the segments adjacent to the proximal and distal edges of the ABSORB everolimus-eluting bioresorbable vascular scaffold: 6-month and 1-year follow-up assessment: a virtual histology intravascular ultrasound study from the first-in-man ABSORB cohort B trial.
Bill D Gogas, Patrick W Serruys, Roberto Diletti, Vasim Farooq, Salvatore Brugaletta, Cecile Dorange

JACC Cardiovasc Interv· June 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The SPIRIT V diabetic study: a randomized clinical evaluation of the XIENCE V everolimus-eluting stent vs the TAXUS Liberté paclitaxel-eluting stent in diabetic patients with de novo coronary artery lesions.
Eberhard Grube, Bernard Chevalier, Giulio Guagliumi, Peter C Smits, Marrianne Stuteville, Cécile Dorange

Am Heart J· May 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Morphological and functional evaluation of the bioresorption of the bioresorbable everolimus-eluting vascular scaffold using IVUS, echogenicity and vasomotion testing at two year follow-up: a patient level insight into the ABSORB A clinical trial.
Giovanna Sarno, Nico Bruining, Yoshinobu Onuma, Scot Garg, Salvatore Brugaletta, Cecile Dorange

Int J Cardiovasc Imaging· January 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Evaluation of the second generation of a bioresorbable everolimus-eluting vascular scaffold for the treatment of de novo coronary artery stenosis: 12-month clinical and imaging outcomes.
Patrick W Serruys, Yoshinobu Onuma, Dariusz Dudek, Pieter C Smits, Jacques Koolen, Cecile Dorange

J Am Coll Cardiol· October 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Angiographic geometric changes of the lumen arterial wall after bioresorbable vascular scaffolds and metallic platform stents at 1-year follow-up.
Josep Gomez-Lara, Salvatore Brugaletta, Vasim Farooq, Robert Jan van Geuns, Bernard De Bruyne, Cécile Dorange

JACC Cardiovasc Interv· July 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Comparison between the first and second generation bioresorbable vascular scaffolds: a six month virtual histology study.
Salvatore Brugaletta, Hector M Garcia-Garcia, Roberto Diletti, Josep Gomez-Lara, Scot Garg, Cecile Dorange

EuroIntervention· April 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A comparative assessment by optical coherence tomography of the performance of the first and second generation of the everolimus-eluting bioresorbable vascular scaffolds.
Josep Gomez-Lara, Salvatore Brugaletta, Roberto Diletti, Scot Garg, Yoshinobu Onuma, Cécile Dorange

Eur Heart J· February 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The SPIRIT V study: a clinical evaluation of the XIENCE V everolimus-eluting coronary stent system in the treatment of patients with de novo coronary artery lesions.
Eberhard Grube, Bernard Chevalier, Peter Smits, Vladimir Džavík, Tejas M Patel, Cécile Dorange

JACC Cardiovasc Interv· February 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis